Clinical Trial to Assess the Efficacy and Safety of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol for the Treatment of Seasonal Allergic Rhinitis (SAR) to Mountain Cedar in Subjects 12 Years and Older

NCT01010971 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

671

Enrollment

INDUSTRY

Sponsor class

Conditions

Seasonal Allergic Rhinitis

Interventions

DRUG: Ciclesonide HFA 160 μg
DRUG: Ciclesonide HFA 80 μg
DRUG: Placebo

Sponsor

Sumitomo Pharma America, Inc.